| Code | CSB-RA011656MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Etokimab, targeting interleukin-33 (IL-33), a nuclear cytokine and alarmin released upon cellular stress or tissue damage. IL-33 functions as a critical immune modulator by binding to its receptor ST2 on various immune cells, including type 2 innate lymphoid cells, mast cells, and Th2 cells, thereby initiating inflammatory cascades. This pathway plays a significant role in allergic inflammation, asthma, atopic dermatitis, and chronic obstructive pulmonary disease, as well as contributing to fibrotic disorders and certain cardiovascular conditions.
Etokimab is a humanized IgG1 monoclonal antibody that neutralizes IL-33 by preventing its interaction with the ST2 receptor, effectively blocking downstream inflammatory signaling. This biosimilar provides researchers with a valuable tool for investigating IL-33-mediated immune responses, exploring disease mechanisms in type 2 inflammation, and evaluating potential therapeutic interventions in preclinical models. The antibody serves as an essential reagent for studies examining alarmin biology and tissue-specific immune regulation.
There are currently no reviews for this product.